Integrated BioPharma Inc (INBP) stock
Close on Oct 19, 2026Market cap $5.59MP/E –Yield –
Integrated BioPharma Inc saw revenue fall 19.3% to $43.87M over the twelve months to Jun 30, 2026. Operating income fell 233.9% to -$2.71M, moving the operating margin from 3.7% to -6.2%. Free cash flow was $895.00K, down 52.2% from a year earlier. At the latest close the market valued the company at $5.59M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $5.59M
- P/E ratio
- –
- Price to sales
- 0.13
- Price to book
- 0.32
- Dividend yield
- –
- Free cash flow yield
- 16.01%
Fundamentals
- Revenue
- $43.87M
- Net income
- -$2.84M
- EPS, diluted
- -$0.09
- Free cash flow
- $895.00K
- Book value per share
- $0.57
- Diluted shares
- 31M
Trading
- Next earnings
- Nov 9, 2026 (estimated, during market hours)
- Previous close
- $0.18
- Open
- $0.18
- Day's range
- $0.18 – $0.18
- Volume
- 0
- Average volume (20 days)
- 23,169
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | INBP | S&P 500 | Difference | INBP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.4% | +0.6% | +10.8 pts | ||
| 3 months | +12.3% | +3.4% | +8.9 pts | ||
| Year to date | -49.3% | +13.3% | −62.6 pts | ||
| 1 year | -41.9% | +16.6% | −58.5 pts | ||
| 3 years | -40.0% | +86.4% | −126.4 pts | -15.7% | +23.1% |
| 5 years | -83.0% | +81.9% | −164.9 pts | -29.9% | +12.7% |
| 10 years | 0.0% | +318.9% | −318.9 pts | 0.0% | +15.4% |
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Integrated BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Results
- Results
About Integrated BioPharma
Pharmaceutical Preparations
Integrated BioPharma, Inc. manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products. The company operates primarily through two segments: Contract Manufacturing and Other Business Lines. Contract Manufacturing produces dietary supplements for distributors, multilevel marketing firms, and specialized health-care providers. The Other Business Lines segment provides warehousing and order fulfillment services while distributing select raw materials. Its customer base is situated mainly in the United States and Luxembourg, with significant business generated from major contract manufacturing accounts.
Company profile, executives and historyIntegrated BioPharma stock: common questions
What is Integrated BioPharma's stock price?
INBP closed at $0.18 on Oct 19, 2026, up 0.00% on the day.
What is Integrated BioPharma's market cap?
Integrated BioPharma was worth $5.59M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is INBP's P/E ratio?
Integrated BioPharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.09), so it has no meaningful P/E ratio.
How much revenue does Integrated BioPharma make?
Integrated BioPharma reported revenue of $43.87M for the twelve months to Jun 30, 2026, down 19.3% from a year earlier.
Does Integrated BioPharma pay a dividend?
No. Integrated BioPharma has not paid a cash dividend over the last twelve months.
When does Integrated BioPharma report earnings next?
Integrated BioPharma is expected to report Q1 FY2027 results on Nov 9, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has INBP stock performed over the past year?
Including dividends, INBP returned -41.9% over the past year, against +16.6% for the S&P 500.
Who are Integrated BioPharma's competitors?
Companies most similar to Integrated BioPharma by business, industry and size include BHST, JAGX, BFRI, LXRX, SIGA.
See a number that looks wrong?